Loading…
Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib
We aimed to determine whether patients receiving dasatinib or imatinib concurrently with high‐dose methotrexate (HDMTX) had slower methotrexate clearance than patients not receiving a tyrosine kinase inhibitor (TKI) during the HDMTX infusion. Patients concurrently receiving dasatinib and HDMTX (N = ...
Saved in:
| Published in: | Pediatric blood & cancer 2019-05, Vol.66 (5), p.e27618-n/a |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3538-682e09016be9f59733cf52895df4c41728f59079309f3125d031a26fdb0d0363 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3538-682e09016be9f59733cf52895df4c41728f59079309f3125d031a26fdb0d0363 |
| container_end_page | n/a |
| container_issue | 5 |
| container_start_page | e27618 |
| container_title | Pediatric blood & cancer |
| container_volume | 66 |
| creator | Ramsey, Laura B. Mizuno, Tomoyuki Vinks, Alexander A. O'Brien, Maureen M. |
| description | We aimed to determine whether patients receiving dasatinib or imatinib concurrently with high‐dose methotrexate (HDMTX) had slower methotrexate clearance than patients not receiving a tyrosine kinase inhibitor (TKI) during the HDMTX infusion. Patients concurrently receiving dasatinib and HDMTX (N = 7) had significantly slower MTX clearance (P = 0.008) than patients not receiving a TKI (N = 111). Two patients receiving a TKI during a HDMTX infusion required glucarpidase. In vitro studies showed that dasatinib significantly inhibited methotrexate uptake by SLCO1B1‐expressing cells (P = 0.009). There may be an interaction between dasatinib and HDMTX, mediated by the transporter SLCO1B1, that causes a delay in MTX clearance. |
| doi_str_mv | 10.1002/pbc.27618 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2194680197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2194680197</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3538-682e09016be9f59733cf52895df4c41728f59079309f3125d031a26fdb0d0363</originalsourceid><addsrcrecordid>eNp1kMlOwzAQQC0EoqVw4AeQJU4c0nqJsxyhrFIlOPQeOc6EumTDdij5ewwp3DjNaPT0RnoInVMyp4SwRZerOYsjmhygKRWhCASh8eHfTtIJOrF269GIiOQYTTiJ4phRPkX1LVRygALX4DatM_ApHWBVgTSyUYB1gzvpNDTO4p12GyxV74FqqLtNm1fSOq1wBf0b1Fpi1TaqN8bT1YANKNAfunnFhbTe0ej8FB2VsrJwtp8ztL6_Wy8fg9Xzw9PyehUoLngSRAkDkhIa5ZCWIo05V6VgSSqKMlQhjVniryROOUlLTpkoCKeSRWWRE79GfIYuR21n2vcerMu2bW8a_zFjNA2jhFAvnaGrkVKmtdZAmXVG19IMGSXZd9fMd81-unr2Ym_s8xqKP_I3pAcWI7DTFQz_m7KXm-Wo_ALh4IKZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2194680197</pqid></control><display><type>article</type><title>Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib</title><source>Wiley</source><creator>Ramsey, Laura B. ; Mizuno, Tomoyuki ; Vinks, Alexander A. ; O'Brien, Maureen M.</creator><creatorcontrib>Ramsey, Laura B. ; Mizuno, Tomoyuki ; Vinks, Alexander A. ; O'Brien, Maureen M.</creatorcontrib><description>We aimed to determine whether patients receiving dasatinib or imatinib concurrently with high‐dose methotrexate (HDMTX) had slower methotrexate clearance than patients not receiving a tyrosine kinase inhibitor (TKI) during the HDMTX infusion. Patients concurrently receiving dasatinib and HDMTX (N = 7) had significantly slower MTX clearance (P = 0.008) than patients not receiving a TKI (N = 111). Two patients receiving a TKI during a HDMTX infusion required glucarpidase. In vitro studies showed that dasatinib significantly inhibited methotrexate uptake by SLCO1B1‐expressing cells (P = 0.009). There may be an interaction between dasatinib and HDMTX, mediated by the transporter SLCO1B1, that causes a delay in MTX clearance.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.27618</identifier><identifier>PMID: 30677213</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acute lymphoblastic leukemia ; Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Child ; Child, Preschool ; dasatinib ; Dasatinib - administration & dosage ; Enzyme inhibitors ; Female ; Follow-Up Studies ; glucarpidase ; Hematology ; Humans ; Imatinib ; Infant ; Leukemia ; Lymphatic leukemia ; Male ; Metabolic Clearance Rate ; Methotrexate ; Methotrexate - administration & dosage ; Oncology ; Pediatrics ; pharmacokinetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; Prognosis ; Protein-tyrosine kinase ; Targeted cancer therapy ; Tissue Distribution ; Young Adult</subject><ispartof>Pediatric blood & cancer, 2019-05, Vol.66 (5), p.e27618-n/a</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3538-682e09016be9f59733cf52895df4c41728f59079309f3125d031a26fdb0d0363</citedby><cites>FETCH-LOGICAL-c3538-682e09016be9f59733cf52895df4c41728f59079309f3125d031a26fdb0d0363</cites><orcidid>0000-0002-8471-9826 ; 0000-0003-4224-2967 ; 0000-0001-6417-3961</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.27618$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.27618$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30677213$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramsey, Laura B.</creatorcontrib><creatorcontrib>Mizuno, Tomoyuki</creatorcontrib><creatorcontrib>Vinks, Alexander A.</creatorcontrib><creatorcontrib>O'Brien, Maureen M.</creatorcontrib><title>Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>We aimed to determine whether patients receiving dasatinib or imatinib concurrently with high‐dose methotrexate (HDMTX) had slower methotrexate clearance than patients not receiving a tyrosine kinase inhibitor (TKI) during the HDMTX infusion. Patients concurrently receiving dasatinib and HDMTX (N = 7) had significantly slower MTX clearance (P = 0.008) than patients not receiving a TKI (N = 111). Two patients receiving a TKI during a HDMTX infusion required glucarpidase. In vitro studies showed that dasatinib significantly inhibited methotrexate uptake by SLCO1B1‐expressing cells (P = 0.009). There may be an interaction between dasatinib and HDMTX, mediated by the transporter SLCO1B1, that causes a delay in MTX clearance.</description><subject>Acute lymphoblastic leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>dasatinib</subject><subject>Dasatinib - administration & dosage</subject><subject>Enzyme inhibitors</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>glucarpidase</subject><subject>Hematology</subject><subject>Humans</subject><subject>Imatinib</subject><subject>Infant</subject><subject>Leukemia</subject><subject>Lymphatic leukemia</subject><subject>Male</subject><subject>Metabolic Clearance Rate</subject><subject>Methotrexate</subject><subject>Methotrexate - administration & dosage</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>pharmacokinetics</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma</subject><subject>Prognosis</subject><subject>Protein-tyrosine kinase</subject><subject>Targeted cancer therapy</subject><subject>Tissue Distribution</subject><subject>Young Adult</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kMlOwzAQQC0EoqVw4AeQJU4c0nqJsxyhrFIlOPQeOc6EumTDdij5ewwp3DjNaPT0RnoInVMyp4SwRZerOYsjmhygKRWhCASh8eHfTtIJOrF269GIiOQYTTiJ4phRPkX1LVRygALX4DatM_ApHWBVgTSyUYB1gzvpNDTO4p12GyxV74FqqLtNm1fSOq1wBf0b1Fpi1TaqN8bT1YANKNAfunnFhbTe0ej8FB2VsrJwtp8ztL6_Wy8fg9Xzw9PyehUoLngSRAkDkhIa5ZCWIo05V6VgSSqKMlQhjVniryROOUlLTpkoCKeSRWWRE79GfIYuR21n2vcerMu2bW8a_zFjNA2jhFAvnaGrkVKmtdZAmXVG19IMGSXZd9fMd81-unr2Ym_s8xqKP_I3pAcWI7DTFQz_m7KXm-Wo_ALh4IKZ</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Ramsey, Laura B.</creator><creator>Mizuno, Tomoyuki</creator><creator>Vinks, Alexander A.</creator><creator>O'Brien, Maureen M.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0002-8471-9826</orcidid><orcidid>https://orcid.org/0000-0003-4224-2967</orcidid><orcidid>https://orcid.org/0000-0001-6417-3961</orcidid></search><sort><creationdate>201905</creationdate><title>Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib</title><author>Ramsey, Laura B. ; Mizuno, Tomoyuki ; Vinks, Alexander A. ; O'Brien, Maureen M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3538-682e09016be9f59733cf52895df4c41728f59079309f3125d031a26fdb0d0363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>dasatinib</topic><topic>Dasatinib - administration & dosage</topic><topic>Enzyme inhibitors</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>glucarpidase</topic><topic>Hematology</topic><topic>Humans</topic><topic>Imatinib</topic><topic>Infant</topic><topic>Leukemia</topic><topic>Lymphatic leukemia</topic><topic>Male</topic><topic>Metabolic Clearance Rate</topic><topic>Methotrexate</topic><topic>Methotrexate - administration & dosage</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>pharmacokinetics</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma</topic><topic>Prognosis</topic><topic>Protein-tyrosine kinase</topic><topic>Targeted cancer therapy</topic><topic>Tissue Distribution</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramsey, Laura B.</creatorcontrib><creatorcontrib>Mizuno, Tomoyuki</creatorcontrib><creatorcontrib>Vinks, Alexander A.</creatorcontrib><creatorcontrib>O'Brien, Maureen M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramsey, Laura B.</au><au>Mizuno, Tomoyuki</au><au>Vinks, Alexander A.</au><au>O'Brien, Maureen M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2019-05</date><risdate>2019</risdate><volume>66</volume><issue>5</issue><spage>e27618</spage><epage>n/a</epage><pages>e27618-n/a</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><notes>This work was presented previously at the Childhood Leukemia Early Adverse Reactions Conference in 2017.</notes><abstract>We aimed to determine whether patients receiving dasatinib or imatinib concurrently with high‐dose methotrexate (HDMTX) had slower methotrexate clearance than patients not receiving a tyrosine kinase inhibitor (TKI) during the HDMTX infusion. Patients concurrently receiving dasatinib and HDMTX (N = 7) had significantly slower MTX clearance (P = 0.008) than patients not receiving a TKI (N = 111). Two patients receiving a TKI during a HDMTX infusion required glucarpidase. In vitro studies showed that dasatinib significantly inhibited methotrexate uptake by SLCO1B1‐expressing cells (P = 0.009). There may be an interaction between dasatinib and HDMTX, mediated by the transporter SLCO1B1, that causes a delay in MTX clearance.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30677213</pmid><doi>10.1002/pbc.27618</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-8471-9826</orcidid><orcidid>https://orcid.org/0000-0003-4224-2967</orcidid><orcidid>https://orcid.org/0000-0001-6417-3961</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2019-05, Vol.66 (5), p.e27618-n/a |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_proquest_journals_2194680197 |
| source | Wiley |
| subjects | Acute lymphoblastic leukemia Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Child Child, Preschool dasatinib Dasatinib - administration & dosage Enzyme inhibitors Female Follow-Up Studies glucarpidase Hematology Humans Imatinib Infant Leukemia Lymphatic leukemia Male Metabolic Clearance Rate Methotrexate Methotrexate - administration & dosage Oncology Pediatrics pharmacokinetics Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis Protein-tyrosine kinase Targeted cancer therapy Tissue Distribution Young Adult |
| title | Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T05%3A35%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Delayed%20methotrexate%20clearance%20in%20patients%20with%20acute%20lymphoblastic%20leukemia%20concurrently%20receiving%20dasatinib&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Ramsey,%20Laura%20B.&rft.date=2019-05&rft.volume=66&rft.issue=5&rft.spage=e27618&rft.epage=n/a&rft.pages=e27618-n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.27618&rft_dat=%3Cproquest_cross%3E2194680197%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3538-682e09016be9f59733cf52895df4c41728f59079309f3125d031a26fdb0d0363%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2194680197&rft_id=info:pmid/30677213&rfr_iscdi=true |